SequelSEC

Rallybio Corp RLYB

Pharmaceutical Preparations · CIK 0001739410 · Fiscal year ends 1231

Revenue
$858.00K
Fiscal year ended 2025-12-31
Operating income
-$33.06M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

Valuation, from the filing

Public float$10.60MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$2.00Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue12.4×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity0.2×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Current ratio14.50x89th
SBC / revenue619.3%87th
R&D / revenue2284.0%84th
Operating margin-3853.6%19th
Revenue YoY growth34.9%70th
Net margin-1046.4%30th

Rallybio Corp (RLYB) reported revenue of $858.00K and net income of -$8.98M for the fiscal year ended 2025-12-31. This page shows 2 annual periods of income statement, balance sheet and cash flow figures normalized from Rallybio Corp’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Rallybio Corp income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-31
Revenue$858.00K$636.00K
Cost of revenueUnavailableUnavailable
Gross profitUnavailableUnavailable
Operating income-$33.06M-$60.50M
Net income-$8.98M-$57.78M
Research & development$19.60M$41.51M
Weighted-average diluted sharesshares 5.63Mshares 5.44M
Pretax income-$8.98M-$55.54M
Income tax expense$0$0
Diluted EPS$-1.59$-10.61
Selling, general & administrativeUnavailableUnavailable
General & administrative$14.32M$19.62M
Selling & marketingUnavailableUnavailable

Balance

Rallybio Corp balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-31
Cash & equivalents$31.37M$13.90M
Total assets$62.26M$68.11M
Current assets$61.25M$67.84M
Total liabilities$4.30M$6.45M
Current liabilities$4.22M$6.24M
Total equity incl. NCI$57.96M$61.65M
Temporary (mezzanine) equityUnavailableUnavailable
InventoryUnavailableUnavailable
Accounts receivableUnavailableUnavailable
GoodwillUnavailableUnavailable
Long-term debtUnavailableUnavailable
Accounts payable$126.00K$278.00K

Cash flow

Rallybio Corp cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-31
Operating cash flow-$29.81M-$49.28M
Capital expendituresUnavailable$0
Investing cash flow$47.27M$33.49M
Financing cash flow$16.00K$5.20M
Net change in cash$17.47M-$10.59M
Stock-based compensation$5.31M$7.99M
Common dividends paidUnavailableUnavailable
Common share repurchasesUnavailableUnavailable
Depreciation & amortization$92.00K$131.00K

Derived

Rallybio Corp derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-31
Free cash flowUnavailableUnavailable
Gross marginUnavailableUnavailable
Operating margin-3853.6%-9511.9%
FCF marginUnavailableUnavailable
SBC / revenue619.3%1256.8%
Current ratio14.50x10.87x
Revenue YoY growth34.9%Unavailable
Net margin-1046.4%-9084.1%
R&D / revenue2284.0%6526.3%
CapEx / revenueUnavailableUnavailable
Long-term debt / equityUnavailableUnavailable
Effective tax rateUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open RLYB in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-10-27View SEC filing
10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-13View SEC filing
10-K · Filed 2026-03-16View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-07View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.